Founded in 2017 Opera Therapeutics is a biopharmaceutical company that is developing next-generation treatments for ocular and neurological diseases.
Read more
We are thrilled to announce that GuRu Wireless Inc. has joined the Kairos Portfolio. GuRu is a wireless communications...
Read more
We're excited to share that our portfolio company, Axial Biotherapeutics, has been selected as one of FierceBiotech's Fierce 15...
Read more
We are delighted to announce that Chimera Bioengineering is the latest company to join the Kairos portfolio. Founded in...
Read more
We are pleased to announce that Transient Plasma Systems (TPS) is the latest company to join the Kairos portfolio....
Read more
Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...
Read more
This month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD) field to its...
Read more
We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made its second investment...
Read more
We are excited to announce that Kairos Venture Partners II, L.P., our second fund, has made its first investment...
Read more
Kairos portfolio company, Compellon, appointed software and services veteran Carv Moore as its Chief Executive Officer to lead the...
Read more